Ovation支架系统治疗腹主动脉瘤的五年长期结果:IDE试验报告
该研究报道了Ovation支架行EVAR治疗腹主动脉瘤的FDA IDE试验5年结果,纳入161例患者,其中41%解剖条件不适合其他支架。5年主要临床成功率为78%,动脉瘤相关死亡率为1%,全因死亡率为25%,无支架移位或开放转换。
要点
- Ovation支架5年主要临床成功率为78%,动脉瘤相关死亡率仅1%。
- 41%患者解剖条件不适合其他支架,仍获得良好长期耐久性。
- 无支架移位和开放转换,I/III型内漏豁免率为95.1%。
核心结论
- Ovation支架在5年随访中表现出良好的长期耐久性,即使41%患者解剖条件不适合其他支架。
- 无支架移位或开放转换,动脉瘤相关死亡率豁免率达99%。
研究设计与样本
- 前瞻性、国际、多中心 pivotal IDE试验,纳入161例择期EVAR治疗的腹主动脉瘤患者。
- 主要纳入标准:AAA直径≥5 cm,近端瘤颈长度≥7 mm,瘤颈角度≤60度,双侧髂动脉固定长度≥10 mm。
主要发现
- 5年主要临床成功率为78%,动脉瘤相关死亡率为1%(1例),全因死亡率为25%。
- I型或III型内漏豁免率为95.1%,二次干预豁免率为80.2%。
- 再干预主要针对II型内漏(24例,63.1%)或分支血栓/狭窄(7例,18.4%)。
- 无支架移位,无患者需开放转换。
关键数值与推荐
- 主要临床成功定义依据SVS指南:成功隔绝动脉瘤且无动脉瘤相关死亡、I/III型内漏、移植物感染或血栓、动脉瘤扩张、破裂、移位或开放转换。
- 技术成功率为100%。
临床怎么用
- 对于解剖条件不适合其他支架的患者,Ovation支架提供了一种微创的标签内血管内治疗选择,可能避免杂交或开放手术。
局限性
- 126例存活患者中仅84例(66.7%)完成5年随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to report the 5-year outcomes of the Food and Drug Administration investigational device exemption clinical trial of endovascular aneurysm repair (EVAR) with the Ovation stent graft (Endologix, Irvine, Calif) for elective treatment of abdominal aortic aneurysm (AAA). METHODS: The study comprised 161 patients who underwent EVAR as part of the prospective, international, multicenter pivotal Ovation stent graft trial. The main inclusion criteria were AAA diameter ≥5 cm, proximal neck length ≥7 mm, neck angulation ≤60 degrees, and bilateral iliac fixation length ≥10 mm. The primary end point was a composite outcome of primary clinical success at 5 years. Primary clinical success was defined in accordance with the Society for Vascular Surgery guidelines as successful aneurysm exclusion without aneurysm-related death, type I or type III endoleak, graft infection or thrombosis, aneurysm expansion, aneurysm rupture, graft migration, or conversion to open repair. Secondary end points included freedom from reintervention, all-cause mortality, and aneurysm-related mortality. RESULTS: Patients were predominantly male (87.6%) and elderly with a mean age of 73 ± 7.7 years; 66 patients (41%) had challenging anatomy and would be considered outside the instructions for use with other stent grafts, 26 (16.2%) had a proximal neck length <10 mm, and 53 (33%) had a minimum access vessel diameter <6 mm. Technical success was 100%. Of 126 surviving patients, 84 (66.7%) completed 5-year follow-up. The 5-year primary clinical success rate was 78%, aneurysm-related mortality was 1% (one patient), and all-cause mortality was 25%. The AAA-related death resulted from AAA post-EVAR rupture at 49 months in a patient who refused treatment for a type IB endoleak. Freedom from type I or type III endoleak was 95.1%. Freedom from secondary interventions was 80.2%. Most of the reinterventions were performed for type II endoleak (24 [63.1%]) or for limb thrombosis or stenosis (7 [18.4%]). There was no graft migration. None of the patients required open conversion. CONCLUSIONS: Five-year results from the Ovation pivotal and continued access investigational device exemption trials demonstrate excellent long-term durability of this endograft despite that 41% of patients had anatomy unfit for other stent grafts. There were no migrations or conversions to open repair and 99% freedom from aneurysm-related mortality. These results suggest a less invasive on-label endovascular option for patients with challenging anatomy who may otherwise require hybrid or open repair.
引用
- Barleben A, Mathlouthi A, Mehta M, et al. Long-term outcomes of the Ovation Stent Graft System investigational device exemption trial for endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2020. PMID: 32249041. doi:10.1016/j.jvs.2020.01.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。